Debiopharm and Aurigene enter licensing pact for onco pathway inhibitor
This article was originally published in Scrip
Executive Summary
Swiss group Debiopharm and Aurigene Discovery Technologies, a subsidiary of Dr Reddy's Laboratories, have entered into an 'option' and exclusive worldwide licence agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.